...
首页> 外文期刊>Emerging Infectious Diseases >Workshop on Use of Intravenous Immunoglobulin in Hand, Foot and Mouth Disease in Southeast Asia (http://wwwnc.cdc.gov/eid/article/21/1/14-0992)
【24h】

Workshop on Use of Intravenous Immunoglobulin in Hand, Foot and Mouth Disease in Southeast Asia (http://wwwnc.cdc.gov/eid/article/21/1/14-0992)

机译:东南亚手足口病静脉注射免疫球蛋白使用研讨会(http://wwwnc.cdc.gov/eid/article/21/1/14-0992)

获取原文

摘要

The South East Asia Infectious Disease Clinical Research Network convened subject matter experts at a workshop to make consensus recommendations for study design of a clinical trial for use of intravenous immunoglobulin (IVIg) in severe hand, foot and mouth disease (HFMD). HFMD is a highly contagious emerging infection among children in the region, a small proportion of whom develop neurologic and cardiopulmonary complications with high case-fatality rates. The use of IVIg for treatment of severe disease is widespread and a part of local, national, and international guidelines, but no clinical evidence warrants the use of this drug, which is expensive and has potentially serious side effects. During a 2-day workshop in March 2014, a group of HFMD experts reviewed the current evidence related to use of IVIg in HFMD and discussed potential study design, feasibility, inclusion and exclusion criteria, sample size, primary and secondary endpoints, and subsidiary studies for a randomized, placebo-controlled trial.
机译:东南亚传染病临床研究网络在研讨会上召集主题专家,就严重手足口病(HFMD)中使用静脉免疫球蛋白(IVIg)的临床试验的研究设计提出共识性建议。 HFMD是该地区儿童中具有高度传染性的新兴感染,其中一小部分患神经系统和心肺并发症,病死率很高。 IVIg用于治疗严重疾病的方法已经广泛使用,并且是地方,国家和国际准则的一部分,但是没有临床证据可以证明该药物的使用是昂贵的,并且具有潜在的严重副作用。在2014年3月举行的为期2天的研讨会中,一群手足口病专家回顾了与在手足口病中使用IVIg相关的现有证据,并讨论了潜在的研究设计,可行性,纳入和排除标准,样本量,主要和次要终点以及辅助研究进行随机,安慰剂对照的试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号